EUROPE ALLOGENEIC HUMAN CHONDROCYTE MARKET ANALYSIS

Allogeneic human chondrocyte is an emerging therapy, which can be used for cartilage repair and other indications. Currently, very few market players are developing these therapies, wherein the studies are in clinical trial phase and are expected to soon receive approval from the regulatory agencies. For instance, Invossa, from Kolon TissueGene, Inc., is expected to be the world’s first cell-and-gene therapy for osteoarthritis. This therapy is going to be a cartilage cells extracted from human cartilage (first fluid of HC) and transformed cells with TGF-β1 (second fluid of TC) by the ratio of 3:1. The product is currently in phase 3 clinical trial phase. This is expected to create lucrative opportunity for players to develop such therapies in the near future.

The Europe allogeneic human chondrocyte market is expected to be valued at US$ 3,440.5 million in 2027 and is expected to exhibit a CAGR of 10.2% during the forecast period (2020-2027).

Figure 1. Europe Allogeneic Human Chondrocyte Market Share (%) in Terms of Value, By Country, 2027

To learn more about this report, Request sample copy

Rising incidence of falls and knee cartilage injuries is expected to propel the market growth during the forecast period

Increasing cases of falls and knee cartilage injuries is a major factor that is expected to propel growth of the Europe allogeneic human chondrocyte market over the forecast period. According to the article published in the British Medical Journal (BMJ Journal) February 2020, the incidence of falls in European countries were as follows in 2017: in the Western European region, 13,840 per 100,000 population seek medical treatment for fall related injury, of which 7,594/100,000 are from Greece and 19,796 are from Norway.

Figure 2. Europe Allogeneic Human Chondrocyte Market Share (%), by Application, 2027

To learn more about this report, Request sample copy

Increasing prevalence of musculoskeletal system disorders is expected to propel the market growth over the forecast period

Increasing cases of musculoskeletal system disorders is expected to drive the market growth during the forecast period. According to the State of Musculoskeletal Health, 2019 report by the Versus Arthritis, the prevalence of musculoskeletal conditions in the U.K. in 2017, was as follows:

Europe Allogeneic Human Chondrocyte Market - Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic is affecting clinical trials, drastically. According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they have stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies.

Furthermore, ongoing clinical trials are being conducted by healthcare facilities and researchers using the following safety measures:

• The healthcare providers are obtaining patient consent through phone or video conferences. According to a survey conducted by Medidata Solutions, Inc. on April 23, 2020, 45% of the respondents opted for virtual/telemedicine for consultancy
• Patients receive a phone call for the screening of COVID-19 symptoms before they schedule in-person visits
• The assessment of the studies are being done in single outpatient areas

Europe Allogeneic Human Chondrocyte Market Restraints:

As the research for human allogeneic chondrocyte is ongoing and products are majorly in the development phase, the research cost and procedures are considerably high and tedious, which can affect the development of such products and is expected to hinder growth of the market.

Moreover, the disadvantages of allogeneic transplantation as compared to autologous transplantation is expected to limit the adoption of allogeneic transplantation, thereby hindering the Europe allogeneic human chondrocyte market growth.

Key Players

Major players operating in the Europe allogeneic human chondrocyte market include Kolon TissueGene, Inc. and ISTO Technologies Inc.